MNKD has yet to reach the levels of NRX that Sanofi did at 2-3 months after the initial launch. And they started started at zero new scripts. And they -- according to the fervent bulls -- were "sandbagging" afrezza.
But more worrisome are the refills that are only just now reaching the levels they were back in December, 2016, when all those mediocre 'contract reps" were selling the drug.
Sorry but there really is no momentum to turn -- period.
News 
Market Data 
Discover 
